Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in treatment‐naïve patients. We evaluated EFV400 and EFV600 pharmacokinetics (NONMEM v. 7.2), assessing patient demographics and genetic polymorphisms (CYP2B6, CYP2A6, CYP3A4, NR1I3) as covariates and explor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Pharmacol Ther
Auteurs principaux: Dickinson, L, Amin, J, Else, L, Boffito, M, Egan, D, Owen, A, Khoo, S, Back, D, Orrell, C, Clarke, A, Losso, M, Phanuphak, P, Carey, D, Cooper, DA, Emery, S
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2015
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4744681/
https://ncbi.nlm.nih.gov/pubmed/26044067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.156
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires